Avacopan for active IgA kidney disease with crescents
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have IgA nephropathy with crescents on a kidney biopsy taken within the last 6 months.
- Your kidney function is moderately reduced (creatinine clearance above 20 mL/min/1.73 m²).
- You have significant protein in your urine (more than 750 mg per day) despite maximum tolerated blood pressure medication.
- You have blood in your urine (more than 10 red blood cells per high-power field).
- You have been on a stable kidney-protective regimen (including blood pressure control and lifestyle measures) for at least 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial tests two study medicines, zigakibart and atrasentan, together for adults with a kidney disease called IgA nephropathy. The goal is to see if this combination helps protect kidney function and reduces protein in the urine.
This trial tests a medication called atrasentan to see if it helps protect kidney function in people with IgA nephropathy, a kidney disease. It may slow down kidney damage and reduce protein in the urine.
This study looks at the long-term safety and effectiveness of atacicept in people with IgA nephropathy (IgAN) who have already completed treatment in a previous atacicept study. It is for patients who want to continue their care and see how well the medicine works over more time.
This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.
This trial tests a medication called avacopan for people with ANCA-associated vasculitis, a condition where the immune system attacks blood vessels. Avacopan is taken with standard treatments to help control the disease and may reduce the need for steroids.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.